Curatis licenses corticorelin to Neupharma in CHF 83.5m Japan deal

Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.

Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.